| Literature DB >> 34088314 |
Takuya Iwasawa1,2, Toshifumi Takahashi3, Eri Maeda4, Koichi Ishiyama5, Satoshi Takahashi6, Ryota Suganuma7, Koki Matsuo8, Masahito Tachibana9, Rie Fukuhara10, Hiromitsu Shirasawa11, Wataru Sato11, Yukiyo Kumazawa11, Yukihiro Terada11.
Abstract
BACKGROUND: Uterine adenomyosis is a benign disease, common among women in their 40 and 50 s, characterised by ectopic endometrial tissue in the uterine myometrial layer. Adenomyosis causes infertility and has a negative effect on the outcomes of in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) embryo transfer (ET) cycles. It has also been reported to have different characteristics depending on the adenomyotic lesion localisation. The effect of its localisation on IVF/ICSI-ET outcomes is unclear. This study aimed to investigate whether adenomyotic lesion localisation, assessed using magnetic resonance imaging (MRI), was associated with outcomes of IVF/ICSI-ET cycles.Entities:
Keywords: Adenomyosis; Adenomyotic lesion; Embryo transfer; Localisation; Magnetic resonance imaging; in vitro fertilisation/intracytoplasmic sperm injection
Mesh:
Year: 2021 PMID: 34088314 PMCID: PMC8176737 DOI: 10.1186/s12958-021-00764-7
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1Flowchart of the participant selection and categorisation throughout the study. MRI, magnetic resonance imaging; ET, embryo transfer
Fig. 2Representative sagittal T2-weighted MRI for each subtype. a Advanced type: the adenomyotic lesion invades the endometrium from the serosa through the full thickness of the myometrium. b Extrinsic type: the adenomyotic lesion is localised to the serosal side of the posterior wall of the uterus. A normal myometrium exists between the adenomyotic lesion and the junctional zone. The arrows show the border between the adenomyotic lesion and the uterine myometrium. c Intrinsic type: the adenomyotic lesion is localised to the endometrial side. The myometrium external to the lesion is intact. The arrows show the border between the adenomyotic lesion and uterine myometrium. MRI, magnetic resonance imaging; EM, endometrium; JZ, junctional zone; BL, bladder. The asterisks show the adenomyotic lesion
Classification of the adenomyotic lesions according to their localisations
| Advanced group ( | Extrinsic group ( | Intrinsic group ( | |
|---|---|---|---|
| 8 (20) | 1 (11.1) | 0 | |
| 4 (10) | 1 (11.1) | 1 (33.3) | |
| 28 (70) | 7 (77.8) | 2 (66.7) |
Patient characteristics
| Advanced group ( | Extrinsic group ( | Intrinsic group ( | ||
|---|---|---|---|---|
| 36 (26–41) | 37 (30–39) | 35 (31–36) | 0.403 | |
| 23 (18.1–32.5) | 19.9 (18.1–23.3) | 23.5 (19.5–25.8) | 0.018 | |
| 41.5 (6–151) | 42 (0–66) | 45 (31–90) | 0.519 | |
| 0.092 | ||||
| 24 (60) | 4 (44.4) | 0 | ||
| 2 (5) | 1 (11.1) | 0 | ||
| 0 | 0 | 1 (33.3) | ||
| 9 (22.5) | 3 (33.3) | 1 (33.3) | ||
| 5 (12.5) | 1 (11.1) | 1 (33.3) | ||
| 17/40 (42.5) | 4/9 (44.4) | 2/3 (66.7) | 0.879 | |
| 7/40 (0–1) | 3/9 (0–1) | 0 | 0.411 | |
| 13/40 (32.5) | 1/9 (11.1) | 2/3 (66.7) | 0.199 | |
| 0 (0–9) | 0 (0–8) | 0 (0–6) | 0.933 | |
| 6/40 (15) | 2/9 (22.2) | 0 | 0.777 | |
| 13/40 (32.5) | 7/9 (77.8) | 1/3 (33.3) | 0.035 | |
| 28/40 (70) | 9/9 (100) | 0 | 0.004 | |
| 28/40 (70) | 5/9 (55.5) | 1/3 (33.3) | 0.324 | |
| 35/40 (87.5) | 7/9 (77.8) | 2/3 (66.7) | 0.354 |
IVF/ICSI-ET in vitro fertilisation/intracytoplasmic sperm injection-embryo transfer
Characteristics of IVF/ICSI-ET
| Advanced group ( | Extrinsic group ( | Intrinsic group ( | ||
|---|---|---|---|---|
| 2 (1–9) | 2 (1–4) | 1 | 0.210 | |
| 0.068 | ||||
| 49/111 (44.1) | 4/21 (19) | 0/3 | ||
| 26/111 (23.4) | 11/21 (52.4) | 1/3 (33.3) | ||
| 16/111 (14.4) | 2/21 (9.5) | 1/3 (33.3) | ||
| 15/111 (13.5) | 3/21 (14.3) | 1/3 (33.3) | ||
| 5/111 (4.5) | 1/21 (4.8) | 0/3 | ||
| 2400 (225–6750) | 2250 (600–2250) | 1425 (1025–2625) | 0.162 | |
| 2 (0–15) | 4 (1–11) | 8 (8–14) | 0.008 | |
| 0.616 | ||||
| 35/106 (33.0) | 6/21 (28.6) | 2/3 (66.7) | ||
| 67/106 (63.2) | 14/21 (66.7) | 1/3 (33.3) | ||
| 4/106 (3.8) | 1/21 (4.7) | 0/3 | ||
| 2 (1–8) | 3 (2–5) | 3 (2–4) | 0.129 | |
| 1 (1–2) | 1 (1–2) | 1 (1–2) | 0.802 | |
| 0.083 | ||||
| 49/100 (49) | 11/27 (40.7) | 1/9 (11.1) | ||
| 51/100 (51) | 16/27 (59.3) | 8/9 (88.9) | ||
| 0.034 | ||||
| 77/100 (77) | 16/27 (59.3) | 9/9 (100) | ||
| 20/100 (20) | 1/27 (3.7) | 0/9 | 0.048 |
IVF in vitro fertilisation; ICSI intracytoplasmic sperm injection; ET embryo transfer; GnRH gonadotropin-releasing hormone
IVF/ICSI fresh and frozen-thawed ET outcomes
| Advanced group ( | Extrinsic group ( | Intrinsic group ( | P | |
|---|---|---|---|---|
| 25/100 (25) | 9/27 (33.3) | 2/9 (22.2) | 0.701 | |
| 16/25 (64) | 3/9 (33.3) | 1/2 (50) | 0.229 | |
| 4/16 (25 %) | 0/3 | 0/1 | n.s. | |
| 9/100 (9) | 6/27 (22.2) | 1/9 (11.1) | 0.137 |
IVF/ICSI in vitro fertilisation/intracytoplasmic sperm injection; ET embryo transfer; n.s. not significant
Logistic regression of IVF/ICSI fresh and frozen-thawed ET outcomes
| Types of adenomyosis | Crude odds ratio | 95 % CI | P-value | Adjusted ORa | 95 % CI | P-value | |
|---|---|---|---|---|---|---|---|
| Clinical pregnancy | Advanced | 1.00 | - | - | 1.00 | - | - |
| Extrinsic | 1.50 | 0.58–3.71 | 0.387 | 1.35 | 0.47–3.77 | 0.564 | |
| Intrinsic | 1.50 | 0.30–6.14 | 0.586 | 1.31 | 0.25–5.65 | 0.725 | |
| Pregnancy loss | Advanced | 1.00 | - | - | 1.00 | - | - |
| Extrinsic | 0.281 | 0.05–1.34 | 0.122 | 0.06 | 0.00–0.54 | 0.026 | |
| Intrinsic | 0.563 | 0.02–15.38 | 0.696 | 1.83 | 0.06–57.62 | 0.701 | |
| Live birth | Advanced | 1.00 | - | - | 1.00 | - | - |
| Extrinsic | 2.89 | 0.89–8.93 | 0.067 | 6.05 | 1.41–29.65 | 0.018 | |
| Intrinsic | 1.26 | 0.06–8.12 | 0.834 | 0.83 | 0.04–5.64 | 0.871 |
aAdjusted odds ratio (OR) for age, prior miscarriage, and body mass index. IVF/ICSI in vitro fertilisation/intracytoplasmic sperm injection; ET embryo transfer; CI confidence interval
Perinatal prognoses
| Total | Advanced group | Extrinsic group | Intrinsic group | |
|---|---|---|---|---|
| 10/16 (62.5) | 7/9 (77.8) | 3/6 (50) | 0/1 | |
| 3/16 (18.8) | 1/9 (11.1) | 2/6 (33.3) | 0/1 | |
| 8/16 (50) | 5/9 (55.6) | 3/6 (50) | 0/1 | |
| 2/16 (12.5) | 1/9 (11.1) | 1/6 (16.7) | 0/1 | |
| 1/16 (6.2) | 1/9 (11.1) | 0/6 | 0/1 | |
| 1/16 (6.2) | 1/9 (11.1) | 0/6 | 0/1 | |
| 1/16 (6.2) | 1/9 (11.1) | 0/6 | 0/1 |